Sort
261,768 grants matching “gene therapy”
Role of lactate transporters in pulmonary fibrosis
$862,439William Michael Oldham · Brigham And Women'S Hospital · R01 · FY2023 · HL
Role of lactate transporters in pulmonary fibrosis
$862,439William Michael Oldham · Brigham And Women'S Hospital · R01 · FY2025 · HL
Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity
$862,420Fabricio Simao · Quiver Bioscience Inc. · R44 · FY2025 · NS
Selective Targeting of the PD-1+ HIV/SIV reservoir with novel anti-PD-1 chimeric antigen receptor T cells
$862,398Karsten Eichholz · Fred Hutchinson Cancer Center · R01 · FY2025 · AI
Innate Immune Clearance of Host-Adapted Pulmonary Pathogens
$862,362Alice S Prince · Columbia University Health Sciences · R35 · FY2022 · HL
Epigenetic HIV Silencing in Macrophages
$862,319Ronald G Collman · University Of Pennsylvania · R33 · FY2020 · AI
Opioid Impacts on T Cell Pathways and Epigenetics to Modulate HIV Integration, Latency and Reservoirs.
$862,316David Mitchell Smith · University Of California, San Diego · R33 · FY2021 · DA
Validation of the ubiquinone synthesis pathway of Toxoplasma gondii as a novel drug target
$862,298Silvia N Moreno · University Of Georgia · R01 · FY2025 · AI
Tissue-specific genetic interactions in cancer
$862,273Kevin Michael Haigis · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)
$862,255David W Crabb · Indiana University Indianapolis · U01 · FY2016 · AA
Project 2 - Vanderbilt University
$862,247James E Crowe · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2019 · AI
Project 2 - Vanderbilt University
$862,247James E Crowe · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2020 · AI
Genetic Determinants of Antidepressant Response
$862,242Francis J McMahon · National Institute Of Mental Health · ZIA · FY2012 · MH
Development and Validation of a Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis
$862,236Evans Fernandez · National Jewish Health · R01 · FY2020 · HL
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs
$862,217Lishan Su · Univ Of North Carolina Chapel Hill · R01 · FY2018 · AI
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational Approach
$862,207R. Brad Jones · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · AI
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer
$862,205Oren Gilad · Aprea Therapeutics, Inc. · R44 · FY2023 · CA
Development of an Oral Therapeutic Drug for Spinal and Bulbar Muscular Atrophy
$862,195Charles C-Y Shih · Androscience Corporation · U01 · FY2011 · NS
BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma
$861,992Damian J. Green · Fred Hutchinson Cancer Research Center · P01 · FY2020 · CA
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
$861,956Raymond Luke Comenzo · Tufts Medical Center · R01 · FY2024 · CA
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing
$861,939Roland Bruno Walter · Fred Hutchinson Cancer Center · R01 · FY2023 · HL
SAM-e Treatment of Depression in Parkinson's Disease
$861,933Beth Israel Medical Ctr (New York) · R01 · FY2002 · AT
A Translational Program of BDNF Gene Delivery in Alzheimer's Disease
$861,854Mark H Tuszynski · University Of California, San Diego · U01 · FY2015 · AG
Identification of common genetic variants for atrial fibrillation and PR interval
$861,837Emelia J. Benjamin · Boston University Medical Campus · R01 · FY2009 · HL
Inhibitors of poxvirus enzymes as novel drugs
$861,830Esteban Edward Mena · Lifepharms, Inc. · U01 · FY2007 · AI